National Institute on Drug Abuse (NIDA)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute on Drug Abuse (NIDA) sits in the top decile of US sponsors by registered trial count (#108 of 15,742 sponsors by registered trial count).
National Institute on Drug Abuse (NIDA): 335 sponsored US clinical trials, 14 recruiting.
National Institute on Drug Abuse (NIDA) sponsors 335 registered US clinical trials on ClinicalTrials.gov, 14 of them currently recruiting, and 292 completed. 30 of these trials are in Phase 3-4 (later-stage) and 202 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cocaine-Related Disorders, with 17 trials.
Top-decile sponsor footprint
National Institute on Drug Abuse (NIDA) ranks in the top decile of sponsors by registered trial count (#108 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
292 of 316 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (92.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
335 total, page 2 of 7
Understanding Drug Abuse Treatment Outcomes
NCT01678833
Health Outcomes by Neighborhood - Baltimore
NCT01571752
Individual Differences in Reward and Impulse Control
NCT01621607
Pexacerfont for Stress-induced Food Craving
NCT01656577
Stem Cell Study of Genetics and Drug Addiction
NCT01534624
Pioglitazone to Treat Opioid Withdrawal Symptoms
NCT01517165
Phase 1 Naltrexone-Bupropion-Methamphetamine Interaction Study
NCT01359930
Brain Functions Underlying Visuospatial Attention Deficits in Schizophrenia
NCT01399437
Brain Circuits in Schizophrenia and Smoking
NCT01369966
Neutral Correlates of Risk-taking in Adolescents Exposed to Drugs Prenatally
NCT01365988
Characterization of Phenotypic and Genotypic Regressors for Imaging
NCT01148381
Nicotinic Modulation of the Default Network of Resting Brain Function
NCT01240616
Automated Prize-based Contingency Management to Increase Counseling Attendance in Opiate-Replacement-Therapy Patients
NCT01229163
Effects of Antipsychotics on Eating and Food Craving in People With Schizophrenia
NCT01222793
Assessment of Cannabis Craving in Schizophrenia Using Virtual Reality
NCT01212081
Interactions Between Intravenous (IV) Cocaine and Lofexidine
NCT01148992
The Effects of Expectation on Natural and Drug -Induced Rewards
NCT01036230
Nicotine Reinforcement and Smoking-Cue Reactivity: Association With Genetic Polymorphisms
NCT01505725
Oral Fluid, Plasma and Whole Pharmacokinetics and Stability Following Smoked Cannabis
NCT01071616
Assessing Top Down and Bottom Up Attention Mechanisms in Smokers Using Nicotine Nasal Spray
NCT01136642
Phase 1 Study to Evaluate RDC-0313 Coadministered With Buprenorphine to Opioid-Experienced Healthy Adults
NCT01046539
Measuring Distress Tolerance With Functional MRI
NCT01038232
Prenatal Drug Exposure: Effects on the Adolescent Brain and Behavior Development
NCT01020669
Risk Perception in Drug-Dependent Adults With and Without Schizophrenia
NCT01031563
Assessment of Craving in Nicotine-Dependent Patients With Schizophrenia Using Virtual Reality
NCT01031433
Developing Field Tools for Real-Time Assessment of Exposure to Psychosocial Stress and Drug Use in an Outpatient Treatment Population
NCT00787423
Brain Glutamate Receptors and Cocaine Dependence
NCT00951314
Pilot Study of Transcranial Magnetic Stimulation (TMS) in Nicotine Addiction
NCT01031693
Reinforcement-Based Treatment for Pregnant Drug Abusers
NCT01177982
Breath Carbon Monoxide and Cotinine as Biomarkers to Distinguish Smokers From Nonsmokers
NCT01031121
Effects of Nicotine on Areas of Impaired and Preserved Functioning in Schizophrenia
NCT01034085
Screening Protocol for the Evaluation of Research Participants at the Maryland Psychiatric Research Center (MPRC)
NCT01030835
Effectiveness of Motivational Interviewing Supervision in Community Programs
NCT01586676
A Multi-Modal Investigation of the Smoking Cessation Medication Varenicline: Dopaminergic Modulation of Reward Processing and Cognitive Control
NCT00830739
Oxytocin and Cognitive Behavioral Therapy in Drug Dependence
NCT00975416
Buprenorphine Naltrexone-P1 A-Cocaine
NCT00733720
Effects of Smoking Cues on Tobacco Craving Responses and the Reinforcing Efficacy of Cigarettes in Adolescent Smokers
NCT01148355
Aripiprazole for Prevention of Relapse to Cocaine Use in Methadone-Maintenance Patients
NCT00780702
Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence
NCT00687713
Vigabatrin Ph 1 Cocaine Interaction Study
NCT00626834
Effects of Smoking on Opioid Receptor Binding: A PET Study
NCT00618631
Effects of Propranolol on Responses to Drug-Related Imagery Scripts
NCT00688805
Phase 2, Multi-Center Trial of Modafinil for Methamphetamine Dependence
NCT00520286
Preventing Substance Use and Risky Behavior Among Rural African American Youth
NCT00535704
The Discriminative Effects of Tramadol in Humans
NCT00499746
PET Imaging of Nicotinic Acetylcholine Receptors
NCT01046513
Optimizing Toxicological Screening in Drug Endangered Children
NCT01037569
Selegiline for Smoking Cessation - 1
NCT00439413
Effects of Sativex(Registered Trademark) and Oral THC on Attention, Affect, Working Memory, Reversal Learning, Physiology and Brain Activation
NCT01037608
A Timeline Study of Alcohol Use and Its Relationship to Insomnia
NCT00580411
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 81 |
| Phase 2 | 121 |
| Phase 3 | 14 |
| Phase 4 | 16 |
What is open in the National Institute on Drug Abuse (NIDA) pipeline
14 recruiting of 335 indexed (4% open); 292 completed (87%).
Phase mix: 30 late (III/IV) vs 202 early (I/II) (early-phase heavy).
Top condition: Cocaine-Related Disorders (17 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute on Drug Abuse (NIDA): open-pipeline peers nationwide
Peers matched on 335 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
National Institute on Drug Abuse (NIDA) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 335 trials (± recruiting share)
- Biogen · 334 trials · 6% recruiting
- National Institutes of Health Clinical Center (CC) · 338 trials · 7% recruiting
- Genentech · 332 trials · 7% recruiting
- Cedars-Sinai Medical Center · 339 trials · 21% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Akebia Therapeutics · 4% recruiting · 24 trials
- Dentsply Sirona Implants and Consumables · 4% recruiting · 24 trials
- Smith & Nephew · 4% recruiting · 72 trials
- Medtronic - MITG · 4% recruiting · 119 trials
Related
What to do with this National Institute on Drug Abuse (NIDA) page
335 registered trials is a research-attention snapshot, not an endorsement of National Institute on Drug Abuse (NIDA) or any single study.
- 14 of National Institute on Drug Abuse (NIDA)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Cocaine-Related Disorders is the condition National Institute on Drug Abuse (NIDA) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cocaine-Related Disorders trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
National Institute on Drug Abuse (NIDA) pipeline card: 335 registered trials from official public datasets.Report a data error.